|
Midwest DNA Repair Symposium Wrap-up
Last month, the Case Comprehensive Cancer Center hosted the 20th Midwest DNA Repair Symposium, held at Thwing Center on the CWRU campus and organized by Drs. Alex Almasan, Junran Zhang and Youwei Zhang.
The symposium attracted 139 attendees from 10 states across the east to midwest region, as well as from Canada and China.
The two keynote speakers,
Drs.
Stephen Kowalczykowski from University of California, Davis and
Lee Zou from
Massachusetts General Hospital, delivered exciting research findings during this meeting
.
Dr Kowalczykowski showed how BRCA1/2-Rad51 regulate DSB repair, whereas
Dr. Zou presented novel findings about A
TR in regulating transcription-coupled stress. The meeting also presented a wide variety of research topics ranging basic m
echanisms underlying the DNA damage response and repair, to replication checkpoints, to cell cycle control, to telomere regulation and to technologies that detect/measure DNA repair.
Sponsors of this exciting event included BGI Inc., Tanon Inc., Cleveland Clinic, University Hospitals, Ohio State University Cancer Center, and CWRU Department of Pharmacology.
ABSTRACT AWARDS
Attendees submitted 79 abstracts for oral and poster presentations - the largest in the history of this meeting series. Ten presenters were recognized for outstanding presentations:
Oral Presentations
Abbey Perl - Case Western Reserve University
"A novel role for Protein Phosphatase 2A (PP2A) in the regulation of replication stress"
Tatinana Moiseeva - University of Pittsburgh
"ATR/Chk1 signaling controls replication initiation in undamaged cells"
Yaqun Teng - University of Pittsburgh
"ROS-induced RNA methylation promotes transcription-coupled homologous recombination"
Rachel Speer - University of Louisville
"Mechanisms of E2F1 suppression of RAD51 in chromate-induced failure of homologous recombination"
Poster Presentations
Brian Yard -
Cleveland Clinic
"Systematic annotation of genetic variants that determine sensitivity to radiation: a pan-cancer encyclopedia"
Lakshani Perera -
Wayne State University
"A novel class of chemicals that react with abasic sites in DNA and specifically kill B cell cancers"
Cassandra Moyer -
The Ohio State University
"Functional characterization of BRIP1 missense alleles: understanding the effects on DNA repair and cancer susceptibility"
Samantha Sanford -
University of Pittsburgh
"Oxidized dNTPs cause telomerase errors and chain termination"
Kayla Conner -
Wayne State University
"Mediation of cisplatin and carboplatin efficacy through the activation of base excision repair and mismatch repair by APOBEC3 enzymes"
Andrea Byrum -
Washington University in St. Louis
"TPX2/Aurora A promote replication fork stability and DNA end resection via negative regulation of 53BP1"
|
Case CCC Experts Part of International "A" Team that Debuts Brain Cancer Atlas
Key members of the team include Case CCC members
Jill S. Barnholtz-Sloan, PhD, Case CCC Associate Director for Bioinformatics and the Sally S. Morley Designated Professor in Brain Tumor Research at CWRU School of Medicine, and
Justin Lathia, PhD, Assistant Professor and Associate Staff of Cellular and Molecular Medicine at the Cleveland Clinic Lerner Research Institute, who along with approximately 80 other internationally renowned neurologists, bioinformaticians, and pathologists from the United States and India recently published details of the Ivy Glioblastoma Atlas in
Science [
Puchalski, Science, 2018].
The atlas maps out comprehensive, visually-rich information on the anatomic and genetic bases of glioblastoma at the cellular and molecular levels associated with the disease. It is aimed at helping researchers and physicians improve the diagnosis and treatment of glioblastoma, including finding new drug targets. While Atlas-based data have been previously available, the new paper in
Science represents the first published research outlining the project in detail.
more>
|
An Old Drug Learns a New Trick: Early Cancer Drug May Help Fight 'Superbugs'
While NOD2 is an attractive target, it acts mainly as a facilitator of immune responses, rather than having a distinct physiological activity of its own. This has made it difficult for researchers to modify its actions in the laboratory. In the new study,
published in Scientific Reports [Jatana, Sci Reports, 2018], Dr. McDonald and her team discovered for the first time that NOD2 activity in the skin is controlled by an enzyme that does in fact have a targetable activity-a protein called CAD.
more>
|
Lymphoma and Leukemia Drug May Also Treat Deadly Brain Cancer
The team of researchers, led by
Shideng Bao, PhD, Case CCC member, and Assistant Professor and Associate Staff in the Cleveland Clinic
Lerner Research Institute Department of Stem Cell Biology & Regenerative Medicine, found that Ibrutinib suppressed tumor growth and increased survival in a preclinical model of GBM. Ibrutinib was significantly more effective in slowing tumor growth than the current standard-of-care GBM chemotherapy drug, Temozolomide, and extended average survival rate by more than 10-fold.
more>
|
Join Team Case CCC!
It's hard to believe there is less than 2 months left before VeloSano weekend!
Team Case CCC is going strong so far, and continuing to recruit at Case CCC institutions.
Remember - to be eligible for Case CCC VeloSano pilot funding you must participate in VeloSano as a rider or volunteer and be a Case CCC member.
We are one of the top teams - join us and help to raise money to fund cancer research in Cleveland!
|
VeloSano Pilot Awardees 2018
Congratulations to the most recent group of pilot awardees supported by VeloSano Bike to Cure. All lead PIs or their lab members
Awards were made as part of a competitive RFA process to multi-investigator teams/projects that align with one of the six Case CCC research initiatives. PIs or their lab members must have participated in the VeloSano Bike to Cure event as a rider, virtual rider, or volunteer.
Alex Huang, MD, PhD
"Novel molecular signatures in
Shh
medulloblastoma
defines immune phenotypes and predicts immunotherapeutic response"
Mark Jackson, PhD
"Combating resistance to immune checkpoint inhibition; identifying
new
targets using in vivo forward
genetics
screening"
Ruth Keri, PhD
"The
oncogenic impact
of LIN9 in
triple negative breast cancer"
Richard Lee, MD
"Identifying the molecular targets of mistletoe lectin I for drug development in hepatocellular carcinoma"
Reshmi Parameswaran, PhD, MS
"Targeting
hexosamine
biosynthetic pathway
for
acute myeloid leukemia
therapy"
Horst von Recum, PhD
"A
refillable drug delivery device capable
of
treating recurrent brain
tumors"
David Wald, MD, PhD
"Targeting
thioredoxin
reductase in
AML"
|
The keynote address will be
delivered Thursday, July 26 at the Tinkham Veale University Center by
Dr. Hsing-Jien Kung, Deputy Director and and Director of Basic Research and Distinguished Professor, Dept. Biochemistry and Molecular Medicine, UC Davis at University of California, Davis.
Thursday's program will also feature an update from Cancer Center Director Dr. Stan Gerson, a judged student/trainee poster session, and a reception.
Friday's program will be held at Corporate College East. The agenda will focus on the scientific initiatives and really get into the research being conducted by our Center. Leaders of the scientific initiatives will provide a brief overview, then we will hear scientific presentations being conducted within those initiatives, plus presentations to highlight exciting services and technology provided by Cancer Center shared resources.
Stay tuned for more details.
Organizing Committee:
John Wang, PhD, (Chair); Stan Gerson, MD; Magdalena Grabowska, PhD; Christopher Hoimes, OD; Damian Junk, PhD; Ruth Keri, PhD; Byron Lee, MD, PhD; Aziz Nazha, MD; Agne Petrosuite, MD; Johnie Rose, MD, PhD; Fred Schumacher, PhD, MPH; Martina Veigl, PhD; Jennifer Yu, MD, PhD; Vinay Varadan, PhD
|
Cancer Stem Cell Conference
Aug 6-8, 2018 | Tinkham Veale
The Case Comprehensive Cancer Center (Case CCC) and National Center for Regenerative Medicine (NCRM) invite you to
Cancer Stem Cell Conference (CSC 2018)! Now in it's third year, CSC 2018 will feature renowned thought leaders in the field of cancer stem cell research. This conference is guaranteed to offer cutting-edge keynote presentations from a variety of niches within the field. Join world-class investigators for this 3-day summit and network with scientists and clinicians advancing cancer stem cell research and therapeutic applications.
Conference Highlights
- The agenda will integrate invited talks from thought leaders in the CSC field with short talks from early-stage investigators and trainees selected from submitted abstracts.
- Pre-conference career development workshop for junior faculty and trainees
- Meet the Editors: Natalie Cain, PhD (CellReports), Mark Landis, PhD (CancerDiscovery) and Teodoro Pulvirenti, PhD (JEM)
- Discussion of NIH grants: Michael Espey, PhD (NCI) and Michelle McGuirl, PhD (NIH)
- Young Investigator Awards available to support travel for senior trainees or junior faculty (less than 5 years from their first independent position).
- Opportunity to share ideas with world-class investigators in stem cell research. 2016 CSC was attended by over 300 from 20 countries and 25 U.S. states. This year's conference is on track to attract a similar crowd of colleagues.
Keynote Speakers
- Norman E. 'Ned' Sharpless, MD (NCI)
- John S. Condeelis, PhD (Einstein)
- Irving Weissman, MD (Stanford)
- Zena Werb, PhD (UCSF)
|
Medcity News - Jun 6, 2018
Recent research on brain metastasis from two disparate primary malignancies (non-small cell lung cancer and gastroesophageal cancer) may impact patient care in each case. Abstracts presented by Cleveland Clinic researchers at the 2016
American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago this weekend communicated related findings.
"Brain metastases is a significant and serious complication of systemic cancers - 10 times more common than primary malignant brain tumors, so this is an important clinical problem we see in clinic every day," said
Dr. Manmeet Ahluwalia, Case Comprehensive Cancer Center, director of Cleveland Clinic's Brain Metastasis Research Program and a study author.
|
Microsoft, Case Western Reserve University partner on magnetic fingerprinting cleveland.com - May 18, 2018
Case Western Reserve University and Microsoft are partnering to advance how doctors can use non-invasive scans to detect disease.
Researchers at CWRU published research in 2013 on "magnetic resonance fingerprinting." Despite the name, this doesn't mean that technicians would get medical information from your fingerprint...
"Quantum computing provides an opportunity to find the truly best way to scan patients," CWRU radiology professor Mark Griswold said in a press release. "We are so excited to explore how far we can push these new quantum and quantum-inspired methods beyond traditional computer algorithms."
|
Opportunities for Pilot Projects in Cancer Disparities Research
Deadline: Jul 2, 2018
The Office of Cancer Disparities Research of the Case Comprehensive Cancer Center is providing seed funding for highly innovative and impactful disparities-focused proposals that will generate key data for larger, nationally competitive grants. Attention to cancer disparities (or catchment area) is a cross-cutting theme across the scientific programs; thus projects aligned with the Center's strategic plan, and specifically the Community and Cancer Health Disparities scientific initiative, are preferred. Collaborative, multi-investigator projects are particularly encouraged. The main goal of this RFA is to stimulate novel research designed to (1) improve understanding of factors that contribute to cancer disparities and (2) develop and test interventions for reducing and ultimately eliminating them. Transdisciplinary, interprogrammatic, and translational approaches are especially encouraged, as are new investigator proposals.
|
NIH BULLETIN- Notices and Funding Opportunities
|
Notices Request for Information on the Development of the FY 2021-2023 Trans-NIH Plan for HIV-Related Research (NOT-OD-18-185)
Notice of Availability of Administrative Supplements to Support Acquisition and Annotation of Biospecimens from Racial/Ethnically Diverse Cancer Patients for the Development of Models for the Human Cancer Models Initiative (HCMI)(NOT-CA-18-076)
Notice of NIBIB Participation in PAR-18-331"Simulation Modeling and Systems Science to Address Health Disparities (R01 Clinical Trial Not Allowed)"(NOT-EB-18-016)
Notice of Availability of Administrative Supplements to NIBIB C3i Participants for Advancing Innovation (NOT-EB-18-018)
Program Announcements Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN) (U54 Clinical Trial Optional) (RFA-TR-18-020) Deadline: Oct 9, 2018
Administrative Supplements for Research on Dietary Supplements (Admin Supp - Clinical Trial Not Allowed)(PA-18-817) Deadline: Oct 15, 2018; Jan 15, 2019; Apr 15, 2019; Oct 15, 2019; Jan 15, 2020; or Apr 15, 2020
Administrative Supplements for Validation Studies of Analytical Methods for Dietary Supplement Constituents (Admin Supp - Clinical Trial Not Allowed)(PA-18-818) Deadline: Oct 15 2018, Jan 15 2019, Apr 15 2019, Oct 15 2019, Jan 15 2020, and Apr 15 2020
Collaborative Activities to Promote Cancer Cachexia Research (Admin Supp - Clinical Trial Not Allowed)(PA-18-821) Deadline: Jul 30, 2018 |
|
|
FOLLOW US
|
EVENTS
|
Tues, Jun 12
Radiation Oncology Grand Rounds
Chad Zender, MD
Associate Professor, Otolaryngology, CWRU/UHCMC
"Partial laryngectomy indications and outcomes"
8:10a Lerner B-151
Cancer Impact Lecture
Lily Wang, PhD
Medical College of Wisconsin
"Chalk Talk"
1p NE1-205
Cancer Biology Seminar
Arishya Sharma, PhD Research Fellow, Almasan Lab, Cancer Biology, Cleveland Clinic "Autophagy and USP14 role in non-homologous end joining"
2p NC1-202
|
Wed, Jun 13
Scott Frank, MD, MS Professor, CWRU "Precision Public Health: Using health information technology to improve our approach to community building"
12p PRCHN conf rm
|
Thurs, Jun 14
Developmental Therapeutics Journal Club
9a R4-013
|
Mon, Jun 18
Cancer Center Research Chalk Talk
1p WRB 3-136
|
Thurs, Jun 21
Developmental Therapeutics Journal Club
9a R4-013
|
ADDITIONAL UPCOMING SYMPOSIUMS & EVENTS
Inaugural AACR International Meeting: Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application
June 22-26, 2018
Boston Marriott Copley Place
ASCO Review
June 27, 2018
InterContinental Hotel, Cleveland
AACI Clinical Research Initiative
Jul 11-12, 2018
Chicago, IL
Case CCC Annual Scientific Retreat
Jul 26-27, 2018
CSC 2018
Aug 6-8, 2018
Tinkham Veale University Center, CWRU
|
PREVIOUSLY ANNOUNCED OPPORTUNITIES
Deadline: Jun 28, 2018
Deadline: Jul 2, 2018
Pre-Application: Jul 25, 2018 Application: Aug 8, 2018
Pre-Application: Jul 25, 2018 Application: Aug 8, 2018
Pre-Application: Jul 25, 2018 Application: Aug 8, 2018
LOI Deadline: Jul 26, 2018
Application: Aug 9, 2018
LOI Deadline: Jul 26, 2018
Application: Aug 9, 2018
Deadline: Aug 31, 2018
LOI Deadline: Sep 6, 2018
Application: Sep 26, 2018
LOI Deadline: Sep 6, 2018
Application: Sep 26, 2018
LOI Deadline: Sep 6, 2018
Application: Sep 26, 2018
Deadline: Open
Deadline: Open
Deadline: Open
Deadline: Open
|
|
|
|